2. Search Result
Search Result
Results for "

YAP

" in MedChemExpress (MCE) Product Catalog:

91

Inhibitors & Agonists

2

Biochemical Assay Reagents

8

Peptides

10

Natural
Products

1

Recombinant Proteins

4

Isotope-Labeled Compounds

6

Antibodies

1

Click Chemistry

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147322
    YAP/TAZ inhibitor-2

    		YAP Cancer
    YAP/TAZ inhibitor-2 is a potent and orally active TEAD-YAP/TAZ inhibitor with an EC50 value of 3 nM. YAP/TAZ inhibitor-2 shows anti-proliferative activity. YAP/TAZ inhibitor-2 shows antitumor activity .
    YAP/TAZ inhibitor-2
  • HY-400902
    YAP/TAZ inhibitor-3

    		YAP Cancer
    YAP/TAZ inhibitor-3 (Compound 24) is a YAP/TAZ inhibitor. YAP/TAZ inhibitor-3 shows firefly luciferase inhibitory activity, with an IC50 < 0.1 μM .
    YAP/TAZ inhibitor-3
  • HY-P2244
    YAP-TEAD-IN-1
    2 Publications Verification

    		 YAP Cancer
    YAP-TEAD-IN-1 is a potent and competitive inhibitor of?YAP–TEAD interaction (IC50=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (Kd=15 nM) than YAP (50-171) (Kd=40 nM) .
    YAP-TEAD-IN-1
  • HY-RS15913
    Yap1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Yap1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Yap1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Yap1 Rat Pre-designed siRNA Set A
    Yap1 Rat Pre-designed siRNA Set A
  • HY-RS15912
    Yap1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Yap1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Yap1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Yap1 Mouse Pre-designed siRNA Set A
    Yap1 Mouse Pre-designed siRNA Set A
  • HY-RS15911
    YAP1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    YAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for YAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    YAP1 Human Pre-designed siRNA Set A
    YAP1 Human Pre-designed siRNA Set A
  • HY-170311
    YAP/TEAD-IN-1

    		YAP Cancer
    YAP/TEAD-IN-1 (compound 4) is a potent YAP and TEAD inhibitor. YAP/TEAD-IN-1 shows antioxidant activity. YAP/TEAD-IN-1 shows antiproliferation activity for tumor cells. YAP/TEAD-IN-1 shows little cytotoxic activity for human normal cells .
    YAP/TEAD-IN-1
  • HY-169316
    YAP/TAZ inhibitor-4

    		YAP Cancer
    YAP/TAZ inhibitor-4 (Compound 45) is an inhibitor of YAP/TAZ, exhibiting TEAD transcriptional activation inhibitory activity by suppressing the binding of YAP or TAZ to TEAD .
    YAP/TAZ inhibitor-4
  • HY-173150
    YAP-IN-1

    		YAP Cancer
    YAP-IN-1 (Compound (+)-1) is an autophagy (Autophagy) inhibitor targeting YAP1. YAP-IN-1 binds to the Hippo pathway transcription factor YAP1 with a Kd of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7-mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. YAP-IN-1 holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.) .
    YAP-IN-1
  • HY-168704
    YAP/TAZ-TEAD-IN-2

    		YAP TAM Receptor Survivin Cancer
    YAP/TAZ-TEAD-IN-2 (Compound 51) is a YAP/TAZ-TEAD inhibitor that inhibits the interaction between YAP/TAZ and TEAD. YAP/TAZ-TEAD-IN-2 suppresses the transcriptional activity of TEAD, with an IC50 of 1.2 nM. YAP/TAZ-TEAD-IN-2 inhibits YAP/TAZ-TEAD target genes expression (Cyr61, CTGF, AXL and Survivin) and breast cancer cell proliferation .
    YAP/TAZ-TEAD-IN-2
  • HY-P2244A
    YAP-TEAD-IN-1 TFA
    2 Publications Verification

    		 YAP Cancer
    YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of YAP-TEAD interaction (IC50=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (Kd=15 nM) than YAP (50-171) (Kd= 40 nM) .
    YAP-TEAD-IN-1 TFA
  • HY-151525
    YAP-TEAD-IN-2

    		YAP Cancer
    YAP-TEAD-IN-2 (compound 6) is a potent YAP-TEAD PPI (protein-protein interaction) inhibitor with IC50 is 2.7 nM .
    YAP-TEAD-IN-2
  • HY-111429
    YAP/TAZ inhibitor-1
    5+ Cited Publications

    		 YAP Cancer
    YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC50 of <0.100 μΜ in firefly luciferase assay .
    YAP/TAZ inhibitor-1
  • HY-153811
    IAG933

    YAP-TEAD-IN-3

    		 YAP Apoptosis Cancer
    IAG933 (YAP-TEAD-IN-3) is an orally available YAP/TAZ-TEAD inhibitor that has anti-tumor effects and promotes apoptosis. IAG933 YAP-TEAD-IN-3 inhibits Avi-human TEAD 4217-434, with an IC50 value of 9 nM .
    IAG933
  • HY-168016
    PROTAC YAP degrader-1

    		PROTACs YAP Cancer
    PROTAC YAP degrader-1 (compound YZ-6) is a PROTAC targeting YAP and also inhibits the nuclear localization of YAP. PROTAC YAP degrader-1 is composed of PROTAC target protein ligand NSC682769 (HY-168017) (red part) and E3 ubiquitin ligase ligand + Linker conjugate (R,S,R)-AHPC-PEG2-C2-boc (HY-168019) (blue+black part), in which the PROTAC Linker used is Acid-PEG2-C2-Boc (HY-140480) and the target protein ligand activity control is Demethyl-NSC682769 (HY-168018) [1] .
    PROTAC YAP degrader-1
  • HY-137479
    TEAD-IN-1

    		YAP Cancer
    TEAD-IN-1 (Compound 2) is potent TEAD autopalmitoylation inhibitor, with an IC50 of 603 nM. TEAD-IN-1 increases the interaction of TEAD and VGLL4. TEAD-IN-1 decreases the interaction of YAP and TEAD. TEAD-IN-1 can be used for the research of cancer .
    TEAD-IN-1
  • HY-162126
    Tubulin polymerization-IN-58

    		Microtubule/Tubulin YAP Cancer
    Tubulin polymerization-IN-58 (Compound K18) is a tubulin polymerization inhibitor with an IC50 of 0.446 μM. Tubulin polymerization-IN-58 also induces the degradation of oncogenic protein YAP via the UPS pathway, thus can be used for cancer research .
    Tubulin polymerization-IN-58
  • HY-155360
    MY-1076

    		YAP Apoptosis Cancer
    MY-1076 is an inhibitor of YAP. MY-1076 induces YAP degradation and cell apoptosis. MY-1076 inhibits MGC-803, SGC-7901, HCT-116 and KYSE450 cells proliferation with IC50 s of 0.019, 0.017, 0.020 and 0.044 μM, respectively .
    MY-1076
  • HY-157083
    mCMY020

    		YAP Cancer
    mCMY020 is a covalent inhibitor of TEAD. mCMY020 effectively reduces YAP (Yes-associated protein)-driven transcription and selectively slows the proliferation of Hippo-deficient cancer cells. mCMY020 can be used in cancer research .
    mCMY020
  • HY-W1005067
    EN171

    		Molecular Glues Hippo (MST) Estrogen Receptor/ERR Others
    EN171 is a covalent ligand that covalently targets both C38 and C96 on 14-3-3 to enhance 14-3-3 interactions with ERα, YAP and TAZ, leading to impaired estrogen receptor and Hippo pathway transcriptional activity. EN171 can not only be used as a molecular glue to enhance native protein interactions but can also be used as a covalent 14-3-3 recruiter in heterobifunctional molecules to sequester nuclear neo-substrates such as BRD4 and BLC6 into the cytosol .
    EN171
  • HY-176171
    Tubulin polymerization-IN-79

    		Microtubule/Tubulin Hippo (MST) YAP Apoptosis Cancer
    Tubulin polymerization-IN-79 (Compound C20) is a tubulin polymerization inhibitor. Tubulin polymerization-IN-79 shows potent antiproliferative activity against esophageal cancer cells (e.g., KYSE450, IC50=0.36 μM; EC-109, IC50=0.63 μM). Tubulin polymerization-IN-79 occupies the colchicine binding site to disrupt microtubule network integrity, activating the Hippo signaling pathway, downregulating the oncogenic protein YAP expression, and inducing G2/M phase arrest and apoptosis in esophageal cancer cells. Tubulin polymerization-IN-79 is promising for research of esophageal cancers .
    Tubulin polymerization-IN-79
  • HY-P1727
    Super-TDU
    5 Publications Verification

    		 YAP Cancer
    Super-TDU is a specific YAP antagonist targeting YAP-TEADs interaction. Super-TDU suppresses tumor growth in gastric cancer mouse model .
    Super-TDU
  • HY-P1727A
    Super-TDU TFA

    		YAP Cancer
    Super-TDU TFA is a specific YAP antagonist targeting YAP-TEADs interaction. Super-TDU TFA suppresses tumor growth in gastric cancer mouse model .
    Super-TDU TFA
  • HY-161573
    BAY-593

    		YAP GGTase Cancer
    BAY-593 is an orally active GGTase-I inhibitor. BAY-593 can block YAP1/TAZ signaling in animals and has antitumor activity .
    BAY-593
  • HY-161573B
    BAY-593 hydrochloride

    		YAP GGTase Cancer
    BAY-593 (hydrochloride) is an orally active GGTase-I inhibitor. BAY-593 (hydrochloride) can block YAP1/TAZ signaling in animals and has antitumor activity .
    BAY-593 hydrochloride
  • HY-156024
    TEAD-IN-6

    		YAP Others
    TEAD-IN-6 (Example 11-1) is a TEAD modulator that blocks the interaction between YAP1/TAZ and TEAD. TEAD-IN-6 can be used in cancer research .
    TEAD-IN-6
  • HY-163173
    TEAD-IN-8

    		YAP Cancer
    TEAD-IN-8 is a novel TEAD inhibitor, which potently and specifically inhibits TEAD-YAP transcriptional activities. TM2, alone or in combination with MEK inhibitors, exhibits potent antiproliferative effects in YAP-dependent cancer cells .
    TEAD-IN-8
  • HY-161443
    TEAD-IN-9

    		YAP Cancer
    TEAD-IN-9 (compound 17) is a TEAD1 inhibitor with an IC50 of 0.29 μM. TEAD-IN-9 targets the palmitoyl pocket of TEAD, thereby effectively inhibiting the binding of YAP-TEAD and blocking the transcriptional function of YAP-TEAD .
    TEAD-IN-9
  • HY-125269
    TED-347
    5+ Cited Publications

    		 YAP Cancer
    TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC50 of 5.9 μM for TEAD4⋅Yap1 protein-protein interaction. TED-347 specifically and covalently bonds with Cys-367 within the central pocket of TEAD4 with a Ki of 10.3 μM. TED-347 blocks TEAD transcriptional activity and has antitumor activity .
    TED-347
  • HY-155338
    SWTX-143

    		YAP Cancer
    SWTX-143 is an orally active YAP/TAZ-TEAD inhibitor that binds to the palmitoylation pocket of all four TEAD isoforms. SWTX-143 causes irreversible and specific inhibition of the transcriptional activity of YAP/TAZ-TEAD and shows antitumor activity .
    SWTX-143
  • HY-B0990
    Thiostrepton
    20+ Cited Publications

    		 Bacterial Antibiotic YAP Infection
    Thiostrepton is a thiazole antibiotic which selectively inhibits FOXM1. FOXM1 binds to YAP/TEAD complex. YAP/TEAD/FOXM1 complex binding at regulatory regions of genes governing cell cycle may impact cell proliferation .
    Thiostrepton
  • HY-141644
    PY-60
    5+ Cited Publications

    		 Annexin A YAP Inflammation/Immunology
    PY-60 is a robust and specific activator of YAP transcriptional activity that targets annexin A2 (ANXA2) with a Kd of 1.4 µM. PY-60 directly binds to ANXA2 and antagonizes its normal cellular function of repressing YAP activity .
    PY-60
  • HY-161573A
    (7S)-BAY-593

    		YAP GGTase Cancer
    (7S)-BAY-593 is the S-enantiomer of BAY-593 (HY-161573). BAY-593 is an orally active GGTase-I inhibitor. BAY-593 can block YAP1/TAZ signaling in animals and has antitumor activity .
    (7S)-BAY-593
  • HY-134955
    VT103
    2 Publications Verification

    		 YAP Cancer
    VT103, an analog of VT101, is an orally active and selective TEAD1 protein palmitoylation inhibitor. VT103 inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation, and disrupts interaction between YAP/TAZ and TEAD. VT103 can be used for the research of cancer .
    VT103
  • HY-B0146
    Verteporfin
    210+ Cited Publications

    CL 318952

    		 YAP Apoptosis Autophagy Photosensitizer Cancer
    Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
    Verteporfin
  • HY-170936
    MY-1576

    		FAK Hippo (MST) YAP Cancer
    MY-1576 is a FAK inhibitor with an IC50 of 8 nM. MY-1576 can activate the Hippo pathway, thereby blocking the regulation of YAP/TAZ. MY-1576 also effectively inhibits tumor growth in the KYSE30 xenograft mouse model, demonstrating good safety, and effectively downregulates the autophosphorylation of FAK and the levels of YAP/TAZ in vivo .
    MY-1576
  • HY-138565
    K-975
    20+ Cited Publications

    		 YAP Cancer
    K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
    K-975
  • HY-B0146R
    Verteporfin (Standard)

    CL 318952 (Standard)

    		 Reference Standards YAP Apoptosis Autophagy Cancer
    Verteporfin (Standard) is the analytical standard of Verteporfin. This product is intended for research and analytical applications. Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
    Verteporfin (Standard)
  • HY-15417
    ML-7 hydrochloride
    20+ Cited Publications

    		 Myosin YAP Cancer
    ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits MLCK (IC50=300 nM). ML-7 hydrochloride also inhibits YAP/TAZ.
    ML-7 hydrochloride
  • HY-150256
    YTP-17

    		YAP Cancer
    YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC50 of 4 nM. YTP-17 shows anti-tumor efficacy .
    YTP-17
  • HY-139603
    MYF-01-37

    		YAP Cancer
    MYF-01-37 is a covalent TEAD inhibitor targeting Cys380. MYF-01-37 has a reversible inhibition on YAP/TEAD interaction .
    MYF-01-37
  • HY-138489
    TRULI
    15+ Cited Publications

    Lats-IN-1

    		 YAP Others
    TRULI (Lats-IN-1) is a potent and ATP-competitive inhibitor of Lats1 and Lats2 kinases. TRULI promotes Yap-dependent proliferation in postmitotic mammalian tissues .
    TRULI
  • HY-147214
    GNE-7883
    2 Publications Verification

    		 YAP Cancer
    GNE-7883 is a pan-TEAD inhibitor that blocks the association of YAP/TAZ with TEAD. GNE-7883 effectively reduces chromatin accessibility at TEAD motifs, inhibits cell proliferation in multiple cell line models, and achieves strong anti-tumor efficacy in vivo. In addition, GNE-7883 effectively overcomes intrinsic and acquired resistance to KRAS (Kirsten rat sarcoma viral oncogene homolog) G12C inhibitors in multiple preclinical models by inhibiting YAP/TAZ activation .
    GNE-7883
  • HY-13417A
    AICAR phosphate
    165+ Cited Publications

    Acadesine phosphate; AICA Riboside phosphate

    		 AMPK Autophagy YAP Mitophagy Endogenous Metabolite Cancer
    AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and mitophagy inhibitor .
    AICAR phosphate
  • HY-168017
    NSC682769

    		Ligands for Target Protein for PROTAC Cancer
    NSC682769 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). NSC682769 can be used for synthesis PROTAC YAP degrader-1 (HY-168016) .
    NSC682769
  • HY-174275
    TEAD1/3/4-IN-1

    		YAP Cancer
    TEAD1/3/4-IN-1 (compound 1) is a TEAD1/3/4 inhibitor that inhibits YAP/TAZ-TEAD interaction and can be used in cancer research .
    TEAD1/3/4-IN-1
  • HY-134956
    VT104
    1 Publications Verification

    		 YAP Cancer
    VT104 is a potent and orally active YAP/TAZ inhibitor. VT104 prevents palmitoylation of endogenous TEAD1 and TEAD3 proteins. VT104 can be used in research of cancer .
    VT104
  • HY-150042
    TDI-011536

    		YAP Cardiovascular Disease Others
    TDI-011536 is a potent Lats kinase inhibitor, interrupts Hippo-Yap signaling and initiates the proliferation of lesioned heartmuscle cells. TDI-011536 can be used in studies of organ conservation and regeneration .
    TDI-011536
  • HY-P10947
    MACTIDE-V

    		Epigenetic Reader Domain YAP Cancer
    MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
    MACTIDE-V
  • HY-168018
    Demethyl-NSC682769

    		Ligands for Target Protein for PROTAC Cancer
    Demethyl-NSC682769 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). Demethyl-NSC682769 can be used in synthesis PROTAC YAP degrader-1 (HY-168016) .
    Demethyl-NSC682769

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: